BioNTech to Pay CureVac, GSK $740M Plus Royalties to Settle mRNA Patent Disputes
Frank Vinluan , 2025-08-08 22:06:00 When BioNTech agreed to acquire rival messenger RNA company CureVac in a $1.25 billion stock deal earlier this summer, some financial analysts said the buyout amounted to an out-of-court settlement of the patent litigation between the two companies. As the acquisition moves closer to completion, BioNTech and CureVac have reached…